Percio S Gulko, MD
- PROFESSOR | Medicine, Rheumatology
Percio Gulko, MD, joins Mount Sinai from North Shore-LIJ in Manhasset, New York where he served as Professor and Director of the Laboratory of Experimental Rheumatology at the Center for Genomics and Human Genetics at the Feinstein Institute for Medical Research. He was also a Professor of Molecular Medicine at Hofstra University and an Attending Physician in the Division of Rheumatology at North Shore University Hospital.
Dr. Gulko completed his medical degree, internship and clinical fellowship in Rheumatology at the Universidade Federal do Rio Grande do Sul. Porto Alegre in Brazil. He came to the United States as a research fellow in the Division of Rheumatology at the University of Alabama at Birmingham, and later completed his residency in Internal Medicine at the Medical College of Georgia in Augusta. He also completed a rheumatology fellowship at the National Institutes of Health, and was a faculty member at the Divisions of Autoimmune and Molecular Disease and Rheumatology at Columbia University’s College of Physicians and Surgeons before joining the Feinstein Institute.
Dr. Gulko has received numerous grants from the NIH, given lectures both nationally and internationally and has been published in leading peer-reviewed journals throughout the world. He serves on the editorial board of Genes and Immunity and Physiological Genomics and is a member of the American College of Rheumatology.
Multi-Disciplinary Training AreasGenetics and Genomic Sciences [GGS], Immunology [IMM], Pharmacology and Therapeutics Discovery [PTD]
MD, Universidade Federal Do R.G.S.
Internship, Internal Medicine, Universidade Federal Do R.G.S.
Residency, Internal Medicine, Medical College of Georgia
Fellowship, Rheumatology, Universidade Federal Do R.G.S.
Fellowship, Rheumatology, National Institutes of Health
Fellowship, Rheumatology, Columbia University Medical Center
The Gulko Lab works on identifying new genes involved in the regulation of arthritis severity and joint damage. These new genes have the potential to become new prognostic biomarkers and new targets for more effective therapies for Rheumatoid Arthritis (RA) and other autoimmune diseases.